Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 11:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 593 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Priming Clear all
Active, not recruiting Phase 2 Interventional

Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer

NCT04114825
View directory record Official record
Conditions
Prostate Cancer Recurrent
Interventions
RV001V, Placebo
Biological · Other
Lead sponsor
RhoVac APS
Industry
Eligibility
18 Years and older · Male only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Clearwater, Florida • Towson, Maryland • Omaha, Nebraska + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 17, 2026, 11:02 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer

NCT05617040
View directory record Official record
Conditions
Prostate Cancer
Interventions
ChAdOx1-PCAQ, MVA-PCAQ
Biological
Lead sponsor
Barinthus Biotherapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
St Louis, Missouri • New York, New York • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 17, 2026, 11:02 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Interdental Papillary Insufficiency

NCT00655889
View directory record Official record
Conditions
Interdental Papillary Insufficiency
Interventions
Autologous Human Fibroblasts (azficel-T)
Biological
Lead sponsor
Castle Creek Biosciences, LLC.
Industry
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Oct 17, 2026, 11:02 PM EDT
Completed Phase 1 Interventional

Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

NCT04084951
View directory record Official record
Conditions
Adult Solid Tumor
Interventions
SQZ-PBMC-HPV, Atezolizumab, Ipilimumab, Nivolumab
Biological · Drug
Lead sponsor
SQZ Biotechnologies
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 17, 2026, 11:02 PM EDT
Terminated Phase 2 Interventional

Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory

NCT05576896
View directory record Official record
Conditions
Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer, Colorectal Cancer Stage IV
Interventions
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 17, 2026, 11:02 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Radiofrequency-based Speckle Tracking Echocardiography to Evaluate Diastolic Function

NCT01182805
View directory record Official record
Conditions
Heart Failure, Diastolic
Interventions
Echocardiography system Ultra DCI Model 5000, Echocardiography machine GE Vivid E9, Diastolic function assessment
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 17, 2026, 11:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Test the Safety of Three Experimental HIV Vaccines

NCT00000946
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
HIV p24/MF59 Vaccine, ALVAC-HIV MN120TMG (vCP205), ALVAC-RG Rabies Glycoprotein (vCP65), rgp120/HIV-1 SF-2
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2001
U.S. locations
7
States / cities
Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 17, 2026, 11:02 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immunogenicity of the IHV01 Protein Vaccine Primed and Co-Administered With HIV DNA CON-S Env Vaccine in Healthy, HIV-1-Uninfected Adults

NCT03505060
View directory record Official record
Conditions
HIV Infections
Interventions
DNA CON-S env, IHV01, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 17, 2026, 11:02 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49

NCT04142242
View directory record Official record
Conditions
Meningococcal Infection (Healthy Volunteers)
Interventions
Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Blood sample
Biological · Other
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
59 Years and older
Enrollment
471 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
33
States / cities
Chandler, Arizona • San Diego, California • Waterbury, Connecticut + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 17, 2026, 11:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate an HIV Envelope Trimer, N332-GT5 gp140, Adjuvanted With SMNP in Adult Participants Without HIV

NCT06033209
View directory record Official record
Conditions
HIV
Interventions
N332-GT5 gp140 (IM, Bolus), N332-GT5 gp140 (IM, Fractioned), N332-GT5 gp140 (SC, Bolus), N332-GT5 gp140 (SC, Fractioned), SMNP (IM, Bolus), SMNP (IM, Fractioned), SMNP (SC, Bolus), SMNP (SC, Fractioned)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
8
States / cities
San Francisco, California • Decatur, Georgia • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 17, 2026, 11:02 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults

NCT07183709
View directory record Official record
Conditions
COVID-19
Interventions
PepGNP-COVID19, Sterile Water for Injection
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
3
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 17, 2026, 11:02 PM EDT
Completed Phase 1 Interventional

Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)

NCT01352650
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
plerixafor, decitabine
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
60 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 17, 2026, 11:02 PM EDT
Active, not recruiting Phase 1 Interventional

A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)

NCT05809752
View directory record Official record
Conditions
Leptomeningeal Disease, Triple Negative Breast Cancer, HER2-positive Breast Cancer
Interventions
Dendritic Cell Vaccine
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 17, 2026, 11:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Optimizing Cortical Priming

NCT07860073
View directory record Official record
Conditions
Stroke, Hemiparesis After Stroke
Interventions
5 Hz Repetitive transcranial magnetic stimulation (rTMS) on the contralesional dorsal premotor cortex (cPMd), 5 Hz Repetitive transcranial magnetic stimulation (rTMS) on the ipsilesional primary motor cortex (iM1)
Device
Lead sponsor
Wan-Wen Liao
Other
Eligibility
50 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 17, 2026, 11:02 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

NCT02439450
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Viagenpumatucel-L, Nivolumab, Pembrolizumab, Pemetrexed
Biological · Drug
Lead sponsor
Heat Biologics
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
16
States / cities
Tucson, Arizona • La Jolla, California • Boca Raton, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 17, 2026, 11:02 PM EDT
Active, not recruiting Not applicable Interventional

Promoting Goals-of-Care Discussions for Patients With Memory Problems and Their Caregivers

NCT05596760
View directory record Official record
Conditions
Dementia, Dementia, Vascular, Mixed Dementias, Alzheimer Disease, Huntington Disease, Lewy Body Disease, Creutzfeldt-Jakob Syndrome, Frontotemporal Lobar Degeneration, Cognitive Dysfunction, Cognitive Aging, Chronic Disease, Palliative Care, Patient Care, Health Care Quality, Access, and Evaluation, Patient Care, Health Communication, Patient Care Planning, Quality of Life
Interventions
Jumpstart Guide
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
1,802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 17, 2026, 11:02 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

NCT03233724
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Esophageal, Malignant Pleural Mesotheliomas
Interventions
Decitabine (DAC), Tetrahydrouridine (THU), Pembrolizumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Oct 17, 2026, 11:02 PM EDT
Completed Phase 3 Interventional Results available

SPIRIT PRIME Clinical Trial

NCT00916370
View directory record Official record
Conditions
Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
Core size Xience Prime, Xience Prime Long Lesion (LL)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
56
States / cities
Fairhope, Alabama • Scottsdale, Arizona • Sacramento, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 17, 2026, 11:02 PM EDT
Completed Phase 2 Interventional Results available

Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR

NCT02497404
View directory record Official record
Conditions
Leukemia, Erythroblastic, Acute, Myelodysplastic Syndromes
Interventions
5-Azacytidine, Fludarabine, Melphalan, Alemtuzumab, Total Body Irradiation
Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 17, 2026, 11:02 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Annual Study for Serum Collection for Immunogenicity and Safety Evaluation in Healthy Children Receiving Fluzone®

NCT00755274
View directory record Official record
Conditions
Influenza, Orthomyxoviridae Infections
Interventions
Influenza Virus Vaccine No Preservative: Pediatric Dose
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 5 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 17, 2026, 11:02 PM EDT
Terminated Phase 2 Interventional

Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL

NCT03911076
View directory record Official record
Conditions
ASC-US, ASC-H, LSIL
Interventions
PVX-2, Placebo
Biological · Other
Lead sponsor
PapiVax Biotech, Inc.
Other
Eligibility
25 Years to 70 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Port Saint Lucie, Florida • Newark, New Jersey • Fairfield, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Oct 17, 2026, 11:02 PM EDT
Completed Not applicable Interventional Results available

Exercise-primed Upper Extremity Motor Practice in Chronic Stroke

NCT04259424
View directory record Official record
Conditions
Stroke
Interventions
Aerobic Exercise + Duck Duck Punch
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 17, 2026, 11:02 PM EDT
Withdrawn Phase 2 Interventional

Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer

NCT02495636
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
CDX-1401, MPDL3280A
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Oct 17, 2026, 11:02 PM EDT
Completed Phase 1 Interventional

H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boo...

NCT02206464
View directory record Official record
Conditions
Influenza
Interventions
A/Shanghai/02/2013 (H7N9) MIV, VRC-FLUDNA071-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 17, 2026, 11:02 PM EDT